Vanguard Portfolio Management’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$114M Buy
6,717,642
+1,675,452
+33% +$25.1M 0.01% 1433
2026
Q2
$73.5M Sell
5,042,190
-191,062
-4% -$3.39M ﹤0.01% 1609
2026
Q1
$99.2M Buy
+5,233,252
New +$84.6M 0.01% 1443

Other funds holding SMMT

Vanguard Portfolio Management's SMMT Position: Q3 2026 in Review

Vanguard Portfolio Management increased its Summit Therapeutics (SMMT) stake by 33% in Q3 2026, buying an estimated $25.1M and bringing the position to 6,717,642 shares worth $114M. The position accounts for 0.01% of the portfolio, ranked #1433.

Vanguard Portfolio Management first reported a position in SMMT in Q1 2026 and has held it in 3 quarters since. 298 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Vanguard Portfolio Management held 6,717,642 shares of Summit Therapeutics worth $114M as of Q3 2026.
  • Vanguard Portfolio Management bought 1,675,452 Summit Therapeutics shares in Q3 2026, an estimated $25.1M.
  • Summit Therapeutics made up 0.01% of Vanguard Portfolio Management's portfolio in Q3 2026, its #1433 holding.
  • Vanguard Portfolio Management first reported a position in Summit Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 298 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.